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ABSTRACT 
 Aim: The aim of this preliminary clinical study is to compare the stress level of 
non-hypertensive and hypertensive subjects by measuring changes in Chromogranin A 
(CgA) level in saliva before and after non-surgical periodontal treatment, scaling and root 
planing (SRP), subjects and to determine if the dental treatment affects the patient’s stress 
level. We will also measure the changes in arterial blood pressure before and after non-
surgical periodontal treatment. Finally, compare if the duration of treatment affects the 
CgA level and blood pressure between non-hypertensive and hypertensive subjects. 
Materials and Methods: Twenty patients participated in the study and only 17 
evaluated. Four hypertensive patients and 13 non-hypertensive patients. Blood pressure 
was measured and saliva samples were collected at consultation visit (T0) and before (T1) 
and after (T2) non-surgical periodontal treatment (SRP). Duration of treatment was 
recorded. 
Results: Concentration	of	CgA	(pmol/ml)	in	the	hypertensive	group	between	T0	–	T2	and	T1	–	T2	was	a	decrease	of	15%	and	46.5%	respectively.	The	non-hypertensive	group	a	decrease	of	71%	and	64.4%	respectively.	For	the	whole	population,	there	was	a	significant	decrease	in	CgA	concentration	between	T0	–	T2	(p-value	=	0.046)	
		 vi 
and	T1	–	T2	(p-value	=	0.032)	with	no	statistical	significance	between	T0	–	T1	(p-value	=0.873).	No	significant	difference	in	change	of	blood	pressure.		
Conclusion: Within the limitations of this study, there was no significant difference in 
blood pressure measurements. Concentrations of CgA decreased significantly after SRP 
compared to before SRP in all groups. A larger sample size is needed in the future. 
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INTRODUCTION  	
Saliva and Chromogranin A 
Saliva is a complex and important fluid of the oral cavity. It maintains oral health 
by buffering pH, assists in wound healing, protects and hydrates the oral mucosa and 
teeth (Proctor, 2016). Saliva is secreted from many minor salivary glands in the oral 
cavity and paired submandibular, sublingual and parotid glands. Sympathetic 
innervations stimulate the parotid and submandibular glands to secrete saliva via acinar 
cells through the salivary ducts (Proctor, 2016). Activation of both sympathetic and 
parasympathetic leads to secretion of salivary proteins. Saliva is then referred to as 
‘augmented’ saliva (Asking, 1985).  
Saliva collection is convenient, non-invasive, accepted by patients and stress free 
compared to collection of blood samples via venipuncture. There are multiple 
commercial collection methods available today. Salivette (Sarstedt ™, Nümbrecht, 
Germany) is a device that uses a cotton roll to extract saliva and transfer it to a tube. Its 
use has been well documented in the literature (Arglebe, 1989; Gröschl et al., 2008). 
Salivettes are considered non-invasive and well suited to use on adults and children 
(Mitsuhata et al., 2012). One disadvantage of such a device is that it yields low volumes 
of saliva compared to spitting in a collection tube. However, it is suitable for cortisol and 
CgA analysis. (Obayashi, 2013). Other devices involve suctioning of the saliva using a 
syringe are more invasive.  
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Chromogranin A is a soluble acidic glycoprotein and the major protein of the 
adrenal medulla chromaffin cells (Simon et al., 1989). It is released from secretory 
granules along with catecholamines by exocytosis from the adrenal medulla and 
sympathetic nerve endings (Daniel T O'connor et al., 1984; Viveros, 1975). In the oral 
cavity it is stored and secreted from serous and ductal cells of the submandibular glands 
and secreted into saliva (Saruta et al., 2005). The activation of the sympatho-adrenal-
medullary systems co-releases catecholamines and chromogranin A preceding the 
hypothalamic-pituitary-adrenocortical axis and elevation of cortisol. This makes salivary 
CgA a sensitive and reliable indicator of psychosomatic stress (Nakane et al., 1998). 
Levels of CgA increase dramatically with physical stress and remain slightly elevated for 
up to 30 minutes after the stressor dissipates, as compared to levels of a-amylase which 
rapidly return to baseline (Gallina et al., 2011). 
Levels of CgA were significantly elevated in patients with xerostomia compared 
to age-matched controls (Shigeyama et al., 2008). These findings were recently 
confirmed in patients with xerostomia resulting from antianxiety and antidepressant drugs 
usage (Ohyama et al., 2015). Furthermore, patients with burning mouth syndrome 
exhibited elevated CgA and cortisol levels compared to controls. CgA was significantly 
higher in the group experiencing constant burning sensation (Shigeyama-Haruna et al., 
2013). Nicotine increased salivary CgA levels produced from periodontal ligament 
fibroblasts in passive smokers compared to active smokers and controls (Sadaoka et al., 
2013). However, studies to determine the effects of smoking on CgA levels after 
cessation of smoking have not been done. 
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Chromogranin A follows a circadian rhythm. It is highest upon awakening and 
then reduced to its lowest point 1 hour later. It remains stable throughout the day and 
increases at night in contrast to an opposite pattern for cortisol (Den et al., 2007).  
Chromogranin A has been associated with many systemic diseases and tumors. 
Levels of salivary CgA are elevated in patients with aggressive periodontitis (Haririan et 
al., 2012) and in elderly Japanese patients with pocket depth ≥5 mm and clinical 
attachment loss ≥6 mm (Hironaka et al., 2008). This association is also present in type 2 
diabetic patients (Kogawa et al., 2016). Salivary CgA levels were elevated in patients 
with epilepsy and present a desirable alternative to serum testing in such cases (Dag et 
al., 2010). However, in most cases levels of salivary and serum CgA are not strongly 
related due to the low level of CgA in saliva compared to serum (Haririan et al., 2012; 
Daniel T. O'Connor, 1983). 
 
Stress 
Stress (stressors) is a part of the daily routine for many individuals. They may be 
due to work, financial, emotional/psychological or physical reasons. Stressors are 
perceived as threats that evoke a cascade of events that lead to neuroendocrine and 
immune reactions. In general the human body uses many adaptive processes and 
techniques to cope. Otherwise they would face potential threats and flee them in order to 
survive. Cannon described these in terms of a “flight–or–fight” and “homeostasis” 
response (Walter B. Cannon, 1929; Walter Bradford Cannon, 1929a). Homeostasis refers 
to returning to a steady state and a “harmonious equilibrium” when faced with different 
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stressors (Chrousos et al., 1992). Failure to achieve homeostasis could lead to a number 
of ailments including but not limited to psychiatric disorders, neurodegenerative 
disorders and organ targeted diseases (Deak et al., 2015).  
In 1936, Hans Seyle, a Vienna-born endocrinologist made a discovery that 
became the basis of stress research while experimenting on rats. He named this the 
“General Adaptation Syndrome” (Selye, 1936) and defined it as “the sum of all non-
specific, systemic reactions of the body which ensue upon long continued exposure to 
stress.” (Selye, 1936, 1946). The syndrome consists of 3 distinctive stages, the alarm 
reaction, resistance and exhaustion. 
The alarm reaction is defined as “the sum of all non-specific systemic phenomena 
elicited by sudden exposure to stimuli to which the organism is quantitatively or 
qualitatively not adapted.” (Selye, 1946). This stage is synonymous with what Cannon 
described as the “flight–or–fight response” (Walter Bradford Cannon, 1929a). During this 
acute stress stage the sympatho-adrenal-medullary system, a physiological connection 
between the sympathetic nervous system and the adrenal medulla, is activated (Dunn et 
al., 1990). Epinephrine and norepinephrine are released from neurons throughout the 
brain leading to a state of increased anxiety and alertness (Chrousos & Gold, 1992). A 
decrease in body temperature, increased heart rate and elevation in blood pressure 
prepare the body to confront or flee the stressful stimuli (Selye, 1936).  
The stage of resistance to chronic stress is defined as “the sum of all non-specific 
systemic reactions elicited by prolonged exposure to stimuli to which the organism has 
acquired adaptation as a result of continuous exposure.”(Selye, 1946). The adrenal glands 
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enlarged in response to stress caused by injections of formalin. This led to the discovery 
of the hypothalamic-pituitary-adrenocortical axis.(Selye, 1936). He noted that the 
symptoms of hormonal changes were still evident after the stress hormone levels returned 
to normal allowing the body to restore the state of “homeostasis” (Selye, 1936).  
The stage of exhaustion: Defined as “the sum of all non-specific systemic 
reactions which ultimately develop as the result of very prolonged exposure to stimuli to 
which adaptation had been developed, but could no longer be maintained.” (Selye, 1946). 
In the process of recovery during the stage of resistance the body utilizes energy to cope 
with stress and achieve homeostasis. However, if the stressor persists eventually that 
energy will be depleted and the body will lose its resistance leading to exhaustion and 
deterioration (Selye, 1936).  
From the previously described events one can conclude that hypothalamic-
pituitary-adrenocortical axis and sympatho-adrenal-medullary system are the signaling 
pathways that are closely associated with stress (Lopez et al., 1999). 
Stress is not limited to adults. It can also have long-term implications for neonates 
(Deak et al., 2015). Premature neonates experience multiple stressful invasive procedures 
during treatment in the Neonatal Intensive Care Unit leading to inflammatory and pain 
responses (Simons et al., 2003). Pain and stress experienced as a newborn infant will 
eventually translate to a blunted response to the stress activation cascade and therefore 
result in decreased recovery from stress (Deak et al., 2015). 
The immune system and inflammatory cytokines play a major role in developing 
systemic disease. Chronic stress is considered to be immunosuppressive whereas during 
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acute stress there is an increased release of pro-inflammatory cytokines such as 
interleukin-1ß (IL-1ß), interleukin-6 (IL-6) and tumor necrosis factor (TNF)-a (Elenkov 
et al., 2002). Rheumatoid arthritis may be caused by decreased cortisol production 
accompanied by increased inflammatory cytokines (Straub et al., 2001). Chronic stress 
leads to obesity as the body secretes cortisol resulting in an increased appetite. It also 
leads to indulgence in a high fat, high carbohydrate “comfort food” diet resulting in 
increased abdominal fat (Dallman et al., 2003). Mental stress has been linked to 
cardiovascular disease via multiple mechanism and pathways. Activation of the 
sympatho-adrenal-medullary system and the hypothalamic-pituitary-adrenocortical axis 
causes the body to undergo impaired glucose tolerance, increased oxidative stress, 
elevated blood pressure, vasoconstriction and platelet activation that are involved in the 
pathogenesis of cardiovascular disease (Inoue, 2014; Selye, 1946). Patients with 
cardiovascular disease such as myocardial infarction and coronary artery disease suffer 
from mental and social stress (Inoue, 2014). 
In dentistry patient stress has been linked to periodontal disease and dental 
treatment in general is stressful to patients. The definition of periodontitis in the 
American Academy of Periodontology’s glossary of terms is “Inflammation of the 
periodontal tissues resulting in clinical attachment loss, alveolar bone loss, and 
periodontal pocketing.”. Patients with psychosocial stress have a high prevalence and 
more severe forms of periodontal disease (R. J. Genco et al., 1999). However, the 
person’s ability to adequately cope with stress is considered more important than the type 
of stress when measuring the severity of periodontal disease (R. J. Genco et al., 1999). 
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Psychosocial stress can have a negative effect on the periodontal status by 
behavioral or immune changes, or a combination or both. Behavioral changes include 
change in diet, initiation or increase in smoking, changes in tooth brushing frequency and 
bruxism. Molecular changes such as alterations in gingival circulation, saliva and 
endocrine hormones (Da Silva et al., 1995; R. J. Genco et al., 1999). 
Acute necrotizing ulcerative gingivitis has been linked to stress (Horning et al., 
1995; Loesche et al., 1982). The resulting elevation of cortisol and catecholamines are the 
main risk factors (Johnson et al., 1986). Personality traits can also be factors (Formicola 
et al., 1970). Dominant personality traits are positively related to necrotizing ulcerative 
gingivitis as these patients are not able to attain homeostasis in stressful situations 
(Formicola et al., 1970). Stress is also considered a risk factor for oral pathologies 
including aphthous stomatitis and herpatic gingivostomatitis (R. Genco et al., 2004). 
 
Hypertension 
Hypertension is often referred to as the “silent killer” as many patients do not 
show any symptoms (Merai et al., 2016). About 1 of 3 adults in the United States has 
hypertension. About half of those with hypertension are uncontrolled due to 3 main 
reasons: (Merai et al., 2016) 
- They are unaware of their hypertension. 
- They are aware of hypertension but are untreated. 
- They are aware of their hypertension and are treated but the treatment does not 
provide adequate control. 
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Some of the major risk factors for hypertension relate to lifestyle decisions. 
Advanced age and high sodium intake are two of the main risk factors. Unhealthy diets 
and lack of physical activity are also risk factors that lead to obesity. It is estimated that 
one third of the United States population are obese (Ogden et al., 2015). Finally, habits 
like excessive alcohol consumption, smoking, use of tobacco products and stress 
contribute to the development of hypertension as reported by the American Heart 
Association (National High Blood Pressure Education, 2004) 
The prevalence of hypertension increases with age ranging from 7.3% for young 
adults to 64.9% to adults over the age of 60. (Yoon et al., 2015) Hypertension is slightly 
more prevalent in males than in females. However, prevalence equalized after the age of 
60 (Yoon et al., 2015). Adults not previously diagnosed with high blood pressure 
between the ages of 55 to 65 have a 90 percent risk of developing hypertension if they 
live to the age of 80-85. (Vasan et al., 2002) 
In the Joint National Committee Report (JNC-7) hypertension is diagnosed when 
an individual’s systolic blood pressure is >140 mm Hg and/or their diastolic blood 
pressure >90 mm Hg. The higher the blood pressure the higher the risk of developing 
cardiovascular disease leading to life threatening events such as heart failure, heart attack, 
stroke and renal disease. The blood pressure classification according to the Joint National 
Committee Report (JNC-7) on the prevention, detection, evaluation and treatment of high 
blood pressure is illustrated in Table 1. (National High Blood Pressure Education, 2004) 
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Blood Pressure 
Classification 
Systolic Blood Pressure 
mmHg 
Diastolic Blood Pressure 
mmHg 
Normal <120  and <80 
Prehypertension 120 - 139 or 80-89 
Stage 1 Hypertension 140 – 159 or 90 - 99 
Stage 2 Hypertension ≥160 or ≥100 
Table 1. Classification of hypertension for adults. 
 
In November 2017, the American Heart Association (AHA) changed the classification as 
shown as Table 2. The category of prehypertension was removed due to hazard ratio and 
a young age factor. However, the clinical management of this category leads to first 
improving life style and by diet alteration (low sodium diet) and exercise. Periodic blood 
pressure readings are crucial to check for unusual patterns. Lifestyle changes are 
absolutely necessary if patients are not candidates for hypertensive medication (National 
High Blood Pressure Education, 2004). 
 
Blood Pressure 
Classification 
Systolic Blood Pressure 
mm Hg 
Diastolic Blood Pressure 
mm Hg 
Normal <120  and <80 
Elevated 120 - 129  and <80 
Stage 1 Hypertension 130 – 139 or 80 - 89 
Stage 2 Hypertension ≥140 or ≥90 
Table 2. Latest Classification of hypertension for adults, November 2017 (AHA) 
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Dentists play a critical role in detecting hypertension due to patients’ frequent 
visits to the dental office. Dentists can be the first to detect and diagnose hypertension in 
patients and refer them to their physician for treatment. A high percentage of patients are 
non-compliant to drug therapy (Cramer et al., 2008; Luscher et al., 1985). Therefore, 
frequent blood pressure readings at the dental office can act as a reminder to patients to 
adhere to their hypertensive drug regimen. 
 Hypertension usually presents as either essential (or primary) or secondary. 
Essential hypertension accounts for about 95% of hypertensive cases. The etiology may 
be unknown or there may be predisposing genetic or environmental factors (Dosh, 2001). 
Secondary hypertension accounts for the remaining 5% of hypertensive cases. The 
etiology is usually of systemic origin and can be identified with comprehensive 
diagnostic tests. The causes of this type of hypertension include congenital organ defects 
(Gupta-Malhotra et al., 2015), renovascular disease, Cushing syndrome, chronic renal 
disease, pheochromocytoma, primary hyperaldosteronism, sleep apnea, thyroid disease 
and drug related (i.e. oral contraceptive hormones) (Dosh, 2001; National High Blood 
Pressure Education, 2004). 
 Hypertension treatment recommended by the JNC-7 include lifestyle changes and 
pharmacological approaches. Lifestyle changes include, but are not limited to, increased 
physical activity, weight reduction and reduced sodium intake producing a mean 
reduction of 4 – 11 mmHg in systolic blood pressure (National High Blood Pressure 
Education, 2004). Pharmacological approaches include thiazide-type diuretics as the 
preferred class of drugs as they demonstrate high efficacy in controlling hypertension and 
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therefore preventing cardiovascular complications (ALLHAT, 2002; Materson et al., 
1993). More than 60% of patients require a combination of two or more drugs from 
different classes in order to control their hypertension (Materson et al., 1993). 
 Patients on hypertensive drugs therapy present with oral manifestations. It is 
important for the dentist to understand and to be able to identify underlying causes to 
properly diagnose and treat those patients. These manifestations include gingival 
hyperplasia which is a common side effect seen in patients treated with calcium channel 
blockers. Angiotensin-Converting Enzyme (ACE) inhibitor effects can manifest as oral 
burning (Brown et al., 2006), metallic taste, delayed wound healing and gingival bleeding 
as a result of neutropenia (Little et al., 2012). Another concern for dentists is the use of 
local anesthetics containing epinephrine which contribute to increased blood pressure and 
heart rate. Adverse effects of epinephrine in local anesthetic in poorly controlled 
hypertensive patients were minimal when modest doses of local anesthetic were used (1 
or 2 cartridges of 2% Lidocaine with 1:100,000 epinephrine) (Bader et al., 2002).  
 Most periodontal procedures, especially periodontal surgery require extended 
time. Therefore, the patients are in a supine position for an extended length of time in the 
dental chair. Changing to an upright position might lead to orthostatic hypotension which 
occurs most frequently in hypertensive patients and can be hazardous to the patient (Ricci 
et al., 2015). 
 The aim of this preliminary clinical study is to compare the stress level of non-
hypertensive and hypertensive subjects by measuring changes in Chromogranin A level 
in saliva before and after non-surgical periodontal treatment, scaling and root planing 
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(SRP), subjects and to determine if the dental treatment affects the patient’s stress level. 
We will also measure the changes in arterial blood pressure before and after non-surgical 
periodontal treatment. Finally, compare if the duration of treatment affects the CgA level 
and blood pressure between non-hypertensive and hypertensive subjects.  
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MATERIALS AND METHODS 
 The study subjects are patients who presented at the Periodontal clinic of Henry 
M. Goldman School of Dental Medicine (SDM) for treatment. The study was approved 
by the Institutional Review Board (IRB) at Boston University #H-33248. Twenty subjects 
were enrolled in the study, 6 with diagnosed hypertension (test group) and 14 without 
hypertension (self-reported) (control group). Eight males and 8 were females with an age 
range of 27 – 70 and an average age of 48.8. The subjects underwent a comprehensive 
periodontal examination and received scaling and root planing treatment as part of their 
comprehensive treatment plan. Subjects were screened by the primary investigator using 
the screening form in Appendix A.  
The inclusion criteria for the study are as follow: 
• Subjects 18 years of age or older 
• Patients of the Henry M. Goldman School of Dental Medicine Department 
of Periodontology 
• Diagnosed with hypertension and controlled by medication (test group) 
• No previous diagnosis of hypertension (control group) 
• Requiring non-surgical periodontal treatment, scaling and root planing 
(SRP) treatment 
The exclusion criteria for the study are as follows: 
• Pregnancy (self-reported) 
• Current smokers (or history of smoking ≤ 7 days from day of consult) 
• Cognitive impairment 
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• Undergoing chemotherapy 
• Diagnosed with Sjögren’s syndrome 
• Presence of xerostomia or dry mouth 
• Taking medication for anxiety/depression. 
• Non-hypertensive patients with elevated blood pressure (SBP ≥140 mmHg 
and/or DBP ≥ 90 mmHg) 
• Patients diagnosed with hypertension showing elevated blood pressure 
(SBP ≥160 mmHg or DBP ≥ 100 mmHg 
After screening eligible patients were informed of the details of the study and consented 
by signing the shown consent form in Appendix B. 
Saliva samples and blood pressure reading were obtained for subjects as follows: 
• Day of initial visit (consultation) as a baseline. (Sample A, T0) 
• On the day of non-surgical treatment (SPR) before administration of local 
anesthesia (Sample B, T1) 
• After the completion of non-surgical treatment (SRP) (Sample C, T2) 
• Duration of non-surgical treatment (SRP) was recorded. 
 Blood pressure readings were taken by the primary investigator using an FDA 
approved noninvasive blood pressure monitor AVANT 2120 (Nonin Medical Inc., 
Minnesota, USA). Saliva was collected at the consultation visit using a non-invasive 
collection device (Salivette®, Sarstedt ™, Nümbrecht, Germany) consisting of a dental 
cotton roll in a collection tube. The cotton roll was placed under the tongue for 5 minutes 
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to allow it to absorb unstimulated saliva from subjects. Before collection of the post-SRP 
samples (sample C) patients were instructed to rinse with sterile water to wash blood 
residue away. After 5 minutes the sample was collected. The delay allowed the saliva to 
return to its original composition. The cotton roll was placed in the collection tube and 
centrifuged for 6 minutes at 1,200 rpm to extract the saliva collected in the cotton roll 
into the reservoir. The saliva samples were then transferred to Eppendorf™ micro-
centrifuge tubes (Fisherbrand™, USA) and labelled using the subject’s code (number), 
sample number (A, B or C) and date of collection. The samples were then placed in an 
Eppendorf™ storage box (Fisherbrand™, USA) and stored at -80ºC until analysis. The 
concentration of Chromogranin A in saliva (pmol/mL) was determined using a YK070 
Chromogranin A (Human) electroimmunoassay kit (Yanaihara Institute, Fujinomiya, 
Japan). The samples were analyzed in duplicate without dilution as per the 
recommendation of the manufacturer. 
 
Statistical Analysis 
Data was analyzed using JMP Pro version 13.2 statistical software and Microsoft Excel 
software. Descriptive statistics (mean, median and standard deviation) were calculated. 
Further analysis was performed as Paired t-test analysis to compare change in 
concentration of CgA at different time points for the whole study population and for the 
non-hypertensive group, also to compare changes of blood pressure measurement at 
different time points. A p-value of <0.05 indicated statistical significance of the results. 
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The null hypothesis: 
• There is no statistically significant difference in mean CgA level between 
hypertensive and non-hypertensive groups at T0 – T2 and T1 – T2. 
• There is no statistically significant difference in mean systolic and diastolic blood 
pressures. 
• There is no statistically significant difference in mean CgA level for the whole 
population at T0 – T2 and T1 – T2. 
The alternative hypothesis: 
• There is a statistically significant difference in CgA levels at T0 – T2 and T1 – T2 
(whole population and between hypertensive and non-hypertensive groups) 
• There is a statistically significant difference in in mean systolic and diastolic 
blood pressures between hypertensive and non-hypertensive individuals. 
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RESULT 
The initial sample size was 20 patients, 6 hypertensive and 14 non-hypertensive. After 
laboratory analysis 3 subjects were excluded due to extreme outlier values (2 
hypertensive and 1 non-hypertensive patients). These patients were excluded from the 
statistical analysis. The mean age for the population was 46.12 years with 47% of the 
population being female. Means and standard deviation of blood pressure measurements 
at the three time points for both groups are listed in Table 3. 
Variable Non-Hypertension Hypertension 
Age (years; mean ± SD)  45.77±9.66 47.25±9.00 
Sex (%) 7 Male (53.8%),  6 Female (46.2%)  
2 Males (50%),  
2 Females (50%)  
Systolic BP mmHg (mean ± SD)     
T0 118±10.15 130.75±10.90 
T1 115.85±13.79 123±2.16 
T2 120.54±15.75 130.25±9.42 
Diastolic BP mmHg (mean ± SD)     
T0 72.15±7.9 82±5.89 
T1 68.85±6.88 76.5±9.26 
T2 72.85±7.57 85.25±6.7 
Table 3 – Demographic and Blood pressure measure across subject groups 
The average change in concentration of CgA (pmol/ml) in the hypertensive group 
between T0 – T2 and T1 – T2 was a decrease of 15% and 46.5% respectively. For the non-
hypertensive group the difference between T0 – T2 and T1 – T2 was a decrease of 71% 
and 64.4% respectively. An overview of the data distribution is illustrated in Figure 1. 
For the whole population, there was a significant decrease in CgA concentration between 
T0 – T2 (p-value = 0.046) and T1 – T2 (p-value = 0.032), however, there was no statistical 
significance between T0 – T1 (p-value =0.873). For the non-hypertensive group, there was 
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a significant decrease of CgA level between T0 – T2 (p-value = 0.003) and T1 – T2 (p-
value = 0.025), however, there was no statistical significance between T0 – T1 (p-value = 
0.399). There was no statistical difference in both systolic and diastolic blood pressure at 
all three time points for the whole population as shown in Table 4. Due to the low 
number of patient samples in the hypertensive group statistical analysis could not be 
performed to compare both groups. The mean duration for the treatment was 61.3±18.8 
minutes. 
 
Figure 1 – Scatter plot showing CgA concentration at different time points for hypertension and non-
hypertensive groups. 
		 Systolic	BP		 Diastolic	BP	
T0	-	T1	 0.439	 0.195	
T0	-	T2	 0.684	 0.658	
T1	-	T2	 0.24	 0.085	
Table 4 – P value for difference in systolic and diastolic blood pressure reading for the whole population at 3 
different time points. 
 
	19		
 
DISCUSSION 
 Human beings experience stress, either physical or psychological, on a routine 
basis during their life. That stress is amplified when dealing with dental treatment due to 
fear or past experiences. In the dental office patients fear injections with anesthetics, 
sound of dental handpiece during filling procedures and the thought of having surgery 
performed such as periodontal or extractions. That fear also translates to anxiety as all 
dental procedures are not visible to the patient, therefore, patients anticipate the 
occurrence of a painful event. This might lead to an exaggerated perception of pain (Eli, 
1993). 
In our study we evaluate concentrations of salivary chromogranin A, an acidic 
glycoprotein that has been shown to be sensitive and reliable to assess psychosomatic 
stress (Nakane et al., 1998). It has an instant effect and a short half-life allowing for 
accurate diagnosis of stress levels in individuals at a given time (Gallina et al., 2011). 
Saliva collection is minimally invasive and stress free to patients making it our preferred 
model for diagnostics.  
 Using a Salivatte collection device that was detailed earlier, had minimal effect on 
patient stress as it is considered a stress-free collection device, however, it yielded 
smaller quantities of saliva in some cases especially in the post-operative (T2) timeline. 
Although these quantities are still sufficient for analysis (Obayashi, 2013), one must 
consider variations in salivary flow rate in patients after procedure, as we have noted that 
in all our samples, post-operative saliva was reduced compared to pre-operative and 
baseline.  
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 In this study, we have evaluated the concentration of CgA level in 6 hypertensive 
and 14 non-hypertensive patients undergoing non-surgical periodontal treatment (SRP). 
Saliva was collected and blood pressure was measured at the time of consultation, pre-
operatively and post-operatively. Our analysis included 4 hypertensive and 13 non-
hypertensive patients, where 3 patients were excluded from analysis due to extreme 
outliers after sample analysis. We speculate that these extreme outliers are due to 
contamination of some samples with blood during post-operative collection. It is has been 
previously shown that blood has a higher concentration of CgA compared to saliva 
(Haririan et al., 2012). This phenomenon poses as a challenge as non-surgical periodontal 
treatment inevitably involves bleeding and the severity of the bleeding is dependent on 
multiple factors including severity of periodontal disease status and drug therapy such as 
antiplatelet or anticoagulants. Therefore, other collection methods might be useful to 
avoid contamination of saliva samples with serum.  
The average duration of treatment calculated in our study was 61.3±18.8 minutes 
for non-surgical periodontal treatment of 1 – 2 quadrants per visit. It is considered a 
considerably shorter procedure time compared to other periodontal surgeries that average 
about 2 – 3 hours. 
Comparing the concentration of CgA of patients pre-operatively and post-
operatively we have found a significant decrease in all groups, hypertensive and non-
hypertensive, after completion of the procedure. These results are in agreement with 
previous studies. Mitsuhata et al concluded in their study that the CgA levels were 
significantly decreased post-operatively compared to pre-operatively in young children  
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suggesting that CgA is a useful stress marker to asses patient stress level pre-operatively 
and therefore taking the necessary stress reducing protocol tailored to that patient 
(Mitsuhata et al., 2012).  
 When comparing patient blood pressure at different time points there was no 
significance between blood pressure between hypertensive and non-hypertensive groups 
at all time points. Our results are in agreement with other studies that demonstrated that 
local anesthetic with a vasoconstrictor (2 cartridges of 2% Lidocaine with 1:100,000 
epinephrine) does not result in fluctuation in blood pressure reading or significant adverse 
effects even to the poorly controlled hypertensive patient (Bader et al., 2002). However, 
heart rate and oxygen saturation would have been better predictors of changes due to 
vasoconstrictor or stress of patients intra-operatively as they reflect immediate changes 
more predictably that blood pressure (Morino et al., 2014). 
Stress and anxiety play a role in elevation of blood pressure, therefore appropriate 
stress-reducing protocols are highly recommended. The key for such protocol is patient 
education. When explaining to the patient about the procedure, what to anticipate and 
how it will have a positive impact on their health and well-being, one should use 
simplified lay terms to relay the information to the patient (little). As a result, the 
clinician will have an educated and well-informed patient with less anxiety and stress 
towards dental treatment. A study has concluded that laughter is a stress reliever as levels 
of CgA were significantly decreased when participants watched a comedy show/film 
following a mentally stressful task (Toda et al., 2012). This suggest that stress relieving 
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protocols are not exclusively pre-operative, however, immediate post-operative care is 
beneficial for our patients. 
We recommend for the future a larger sample size to be able to adequately 
perform statistical analysis to confirm if there is a difference in CgA level between 
hypertensive and non-hypertensive patients.  
 
	23		
 
CONCLUSIONS 
Within the limitations of this preliminary study in regards to sample size and post-
operative sample collection, we conclude that: 
• There is a statistically significant difference in CgA levels at T0 – T2 and T1 – T2 
for the whole population. 
• There is no statistically significant difference in mean CgA level between 
hypertensive and non-hypertensive groups at T0 – T2 and T1 – T2. 
• There is no statistically significant difference in mean systolic and diastolic blood 
pressures between groups and the whole population. 
Although there was no statistical difference between non-hypertensive patients and 
hypertensive patients during non-surgical periodontal treatment visits, due to sample size, 
there was a statistical difference when the whole study population was taken into account. 
It is important to follow stress reducing protocols to ensure that patients receive the best 
care possible and avoid any stressful situations that might cause some patients not to 
continue treatment due to those stressors.  
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APPENDIX A 
SCREENING FORM 
 
 
Screening Form 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
Questions YES NO 
Are you 18 years of age or older?   
Are you pregnant?   
Do you have any condition that affects your judgment?   
Are you undergoing any chemotherapy?   
Do you use any tobacco products?   
If you quit using tobacco products, has it been 7 days or more 
since you quit? 
  
Do you have Sjogren’s syndrome?   
Do you often have a dry mouth?   
Have you been diagnosed with high blood pressure?   
If yes, are you taking medication for your blood pressure?   
Are you taking any medication for anxiety?   
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 APPENDIX B 
CONSENT FORM 
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